Binding of the B-Raf inhibitors dabrafenib and vemurafenib to human serum albumin: a biophysical and molecular simulation study M Russi, G Cavalieri, D Marson, E Laurini, S Pricl Molecular Pharmaceutics 19 (5), 1619-1634, 2022 | 13 | 2022 |
Biophysical and docking study on the interaction of anticancer drugs encorafenib and binimetinib with human serum albumin G Cavalieri, G Cilurzo, L Pettorosso, A Mansueto, E Laurini, S Pricl European Journal of Pharmaceutical Sciences 189, 106550, 2023 | 5 | 2023 |
Molecular Ballet: Investigating the Complex Interaction between Self-Assembling Dendrimers and Human Serum Albumin via Computational and Experimental Methods G Cavalieri, D Marson, N Giurgevich, R Valeri, F Felluga, E Laurini, S Pricl Pharmaceutics 16 (4), 533, 2024 | 2 | 2024 |
Into the Groove: A Multitechnique Insight into the DNA–Vemurafenib Interaction G Cavalieri, R Pison, D Marson, E Laurini, S Pricl Applied Biosciences 3 (4), 468-483, 2024 | | 2024 |
361 (PB349): Dendrimers in cancer therapy: exploring protein corona interactions for enhanced drug delivery and theragnostic applications G Cavalieri, E Laurini, D Marson, S Pricl European Journal of Cancer 211, 114874, 2024 | | 2024 |
Beyond the Veil: Free Energy Profiles and Partition Coefficients for Antimelanoma Drugs in Self-Assembled Nanomicelles via COSMOmic and Atomistic Molecular Dynamics Simulations A Mio, D Marson, G Cavalieri, M Fermeglia, E Laurini, S Pricl Journal of Chemical & Engineering Data, 2024 | | 2024 |
Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations S Pricl, E Laurini, D Marson, G Cavalieri MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
Abstract C153: Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations S Pricl, E Laurini, D Marson, G Cavalieri Molecular Cancer Therapeutics 22 (12_Supplement), C153-C153, 2023 | | 2023 |